Guanhao Bio: First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

Express News | The concept of medical consumables surged amid market volatility, with Yingke Medical rising over 10%, hitting a more than four-year high.

BreakingsApr 7 10:16

Guanhao Biotech (300238): Revenue up 2.7% year-over-year in 25 years; Benvelomod revenue surges significantly.

Event: The company released its annual report for 2025. The company achieved operating revenue of 388 million yuan (a year-on-year increase of 2.72%) and net profit attributable to shareholders of the listed company amounted to 24 million yuan (a year-on-year decrease of 11.20%). Excluding non-

Southwest SecuritiesMar 28 00:00

Guan Hao Biology: 2025 Annual Report

SZSIMar 26 00:00 · Announcements

Guan Hao Biology: 2025 Annual Report Summary

SZSIMar 26 00:00 · Announcements

Guanhao Bio (300238.SZ): Independent Director Han Junmei has completed her term and stepped down.

Gelonghui, March 11th - Crown Bioscience (300238.SZ) announced that Ms. Han Junmei, an independent director of the company, has served as an independent director since March 13, 2020, and her continuous term of service has reached six years. According to the relevant provisions of the 'Administrative Measures for Independent Directors of Listed Companies': “The term of office of independent directors shall be the same as that of other directors of the listed company. Upon the expiration of the term, they may be re-elected for consecutive terms, but their consecutive service shall not exceed six years.” Therefore, after Ms. Han Junmei’s term expires, she will no longer serve as an independent director of the company’s sixth board of directors or hold any positions in the various specialized committees of the board. As of the date of this announcement, Ms. Han Junmei has not...

Gelonghui FinanceMar 11 17:26